A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

Phase 2 Not yet recruiting 40 enrolled M.D. Anderson Cancer Center BeOne Medicines · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of zanubrutinib, sonrotoclax, and obinutuzumab can help to control previously untreated CLL/SLL.

Timeline

Start: 2026-12-31
Primary completion: 2027-04-30
Completion: 2029-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obinutuzumab	Monoclonal antibody	—	Oral
Subject	Sonrotoclax	Other / unclassified	320 mg	Oral
Subject	Zanubrutinib	Small molecule	320 mg	Oral

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications